Research brief
Jazz Pharmaceuticals ended the week at 247.5 USD, up 1.5%, keeping a 43-week active Trend Signal intact and leaving the stock near the top of its yearly range. The Healthcare tape was soft on the week and Biotechnology fell harder, making JAZZ’s relative performance useful evidence, though lighter volume and a wide Fair Value premium argue for close monitoring rather than complacency.
- JAZZ rose 1.5% for the week, with gains of 10.2% over four weeks and 26.0% over 12 weeks.
- The close at 247.5 USD sits 23.8% above the 200.0 USD weekly Trend Line and 1.2% below the 250.5 USD 52-week high.
- Sharemaestro Fair Value is 137.3 USD, leaving the stock 80.3% above that reference point after a 119.3% 52-week gain.
- Volume was 3.1M shares, only 0.7x the 13-week average of 4.3M and also 0.7x the 52-week average of 4.5M.
- Biotechnology context is supportive, with 62.0% trend breadth, 78.0% positive Market Dynamics breadth and 66.0% positive Relative Strength breadth, even as the industry averaged a 2.8% weekly decline.
Price action keeps the weekly trend intact
Jazz Pharmaceuticals closed the latest completed week at 247.5 USD, up 1.5%, extending a strong intermediate move without much distance left to the 52-week high of 250.5 USD. The stock is now positioned at 98.0% of its annual range, well above the 105.0 USD low, with 4-week, 12-week and 26-week returns of 10.2%, 26.0% and 46.1%, respectively.
The Trend Signal remains active after 43 active weeks out of the past 52, an 82.7% trend-breadth reading for the stock. Price is 23.8% above the 200.0 USD Trend Line, so the weekly regime is still constructive. The caution is valuation distance: the 137.3 USD Sharemaestro Fair Value reference leaves JAZZ trading 80.3% above fair value, a sign of premium demand but also a larger air pocket if momentum loses support.
Biotech breadth helps the case, while Healthcare is less convincing
The sector backdrop is mixed. US Healthcare stocks averaged a 0.7% weekly decline, with only 48.0% of the sector in active weekly trends and 41.0% showing positive Relative Strength. Against that, JAZZ’s 1.5% weekly gain and positive Market Dynamics and Relative Strength readings stand out, placing it around the 74th percentile across the wider US Healthcare peer set.
The industry picture is more constructive. US Biotechnology averaged a 2.8% weekly loss, but internal breadth remains firmer than the sector, with 62.0% trend breadth, 78.0% positive Market Dynamics breadth and 66.0% positive Relative Strength breadth. JAZZ ranked 18th in its 100-stock biotechnology group for the week and 24th over 12 weeks, although its 10.2% four-week move lagged the industry average of 11.2%.
Market Dynamics are positive, but urgency has cooled
Sharemaestro’s Market Dynamics read remains positive at 0.63, and Relative Strength is positive at 29.57, helped by a 96.1% four-week improvement in the RS measure. The setup remains classified as a continuation profile, and the next-week expectancy read is positive at 55.11% for similar historical states.
The cleaner concern is that activity pressure has fallen 44.6% over four weeks, and the current signal state shows no fresh buy from activity pressure. That does not break the trend, but it does mean the latest price push near the high is relying more on the existing trend backdrop than on fresh acceleration.
Volume and risk leave the breakout test unresolved
Participation did not confirm the latest move emphatically. JAZZ traded 3.1M shares in the week, below the 13-week average of 4.3M and the 52-week average of 4.5M, for a 0.7x volume ratio on both measures. Earlier upside weeks, including the 10.4% gain in late February on 10.5M shares and the 11.4% gain in early May on 6.2M shares, carried stronger participation than the latest advance.
Risk statistics are still orderly: 13-week weekly volatility is 4.0%, below the 52-week baseline of 5.1%, and the past year shows 32 positive weeks against 20 negative weeks. Average positive weeks have been larger than average losing weeks, at 4.2% versus -2.5%. Still, 13 reversal markers in the recent smart-money tape and the stock’s proximity to its high make the next test straightforward: whether JAZZ can take out the 250.5 USD high with volume moving above its baseline, or whether cooling activity pressure starts to matter.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/jazz-pharmaceuticals-43-week-trend-signal-volume-thins/.
Media and research systems can follow the RSS feed or JSON feed.